[A case of primary aldosteronism presenting hypokalemic myopathy induced by benidipine hydrochloride; a dihydropyridine calcium channel blocker].
We report a 46-year-old man with primary aldosteronism presenting hypokalemia, periodic paralysis and hypokalemic myopathy whose clinical course paralleled with the dosage of benidipine hydrochloride, a dihydropyridine calcium channel blocker (DHP-CCB), administered for the treatment of hypertension. To see relations between DHP-CCB and episodes of motor weakness in patients with primary aldosteronism, we surveyed retrospectively the history of motor weakness and anti-hypertensive drugs in 14 consecutive cases with primary aldosteronism in our institute. Five patients out of 11 cases (45.5%) who had received DHP-CCB experienced muscle weakness, however, the rest of three patients receiving other anti-hypertensive drug had not experienced weakness. Though, less attention has been paid as thiazide diuretics, it is reported that DHP-CCB also induces hypokalemia through several mechanisms. However, the occurrence of motor weakness by DHP-CCB is very rare. Our results show that primary aldosteronism should be taken into account when we encounter patients manifesting episodic motor weakness by the use of DHP-CCB.
Sugawara
H
H
Department of Integrated Medicine, Omiya Medical Center, Jichi Medical School.
Shiraiwa
H
H
Otsuka
M
M
Ueki
A
A
D002121:Calcium Channel Blockers / Q000009:adverse effects*; D004095:Dihydropyridines / Q000009:adverse effects*; D006801:Humans; D006929:Hyperaldosteronism / Q000150:complications*; D007008:Hypokalemia / Q000139:chemically induced*; D020514:Hypokalemic Periodic Paralysis / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D009135:Muscular Diseases / Q000139:chemically induced*
D002121:Calcium Channel Blockers; D004095:Dihydropyridines; C061004:benidipine